1 COVID-19 Sex-disaggregated Data Tracker – Global Health 50/50.
https://globalhealth5050.org/covid19/sex-disaggregated-data-tracker/ (accessed 19 Aug 2020).
2 Office fédéral de la santé publique. Rapport sur la situation épidémiologique en Suisse et dans la Principauté de Liechtenstein – semaine 33. 2020. https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/covid-19-woechentlicher-lagebericht.pdf.download.pdf/OFSP_COVID-19_rapport_hebdomadaire.pdf
3 Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. 2020;11.
doi:10.1186/s13293-020-00304-9
4 Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280.e8.
doi:10.1016/j.cell.2020.02.052
5 Muus C, Luecken MD, Eraslan G, et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv. 2020;2020.04.19.049254.
doi:10.1101/2020.04.19.049254
6 Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 inmen and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020;41:1810–7.
doi:10.1093/eurheartj/ehaa373
7 Swärd P, Edsfeldt A, Reepalu A, et al. Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit. Care. 2020;24.
doi:10.1186/s13054-020-02942-2
8 Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc. Res. 2002;53:672–7.
doi:10.1016/S0008-6363(01)00479-5
9 Aguilar-Pineda JA, Albaghdadi M, Jiang W, et al. Structural and functional analysis of female sex hormones against SARS-Cov2 cell entry. Cold Spring Harbor Laboratory. 2020.
doi:10.1101/2020.07.29.227249
10 Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31:1040–5.
doi:10.1016/j.annonc.2020.04.479
11 Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The «Gabrin sign». J Am Acad Dermatol. 2020;83:680–2.
doi:10.1016/j.jaad.2020.05.079
12 Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020;83:308–9.
doi:10.1016/j.jaad.2020.04.032
13 Goren A, Vaño-Galván S, Wambier CG, et al. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity. J. Cosmet. Dermatol. 2020;19:1545–7.
doi:10.1111/jocd.13443
14 Walker RF, Zakai NA, Maclehose RF, et al. Association of Testosterone Therapy with Risk of Venous Thromboembolism among Men with and Without Hypogonadism. JAMA Intern Med. 2020;180:190–7.
doi:10.1001/jamainternmed.2019.5135
15 Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54–67.
doi:10.1007/s11239-020-02134-3
16 Golan R, Scovell JM, Ramasamy R. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male. 2015;18:201–4.
doi:10.3109/13685538.2015.1052392
17 Rastrelli G, Di Stasi V, Inglese F, et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2020;00:1–11.
doi:10.1111/andr.12821
18 Dutta S, Sengupta P. SARS-CoV-2 and Male Infertility: Possible Multifaceted Pathology. Reprod Sci. 2020;1.
doi:10.1007/s43032-020-00261-z
19 Salonia A, Corona G, Giwercman A, et al. SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project. Andrology. 2020 May 5. Online ahead of print.
doi:10.1111/andr.12811
20 Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–38.
doi:10.1038/nri.2016.90
21 Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;1–9.
doi:10.1038/s41586-020-2700-3
22 Gebhard CBSBT-SSTVKSL. GECC-FAMASMR-ZV. Impact of Sex and Gender on COVID-19 outcomes: Role of ACE-2, TMPRSS2, and gender-specific risk factors. SNF Covid-19 Res. Proj. 2020.
23 Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565–82.
doi:10.1016/S0140-6736(20)31561-0
24 Capraro V, Barcelo H. The effect of messaging and gender on intentions to wear a face covering to slow down COVID-19 transmission. Published Online First: 2020.
doi:10.31234/osf.io/tg7vz
25 Office fédéral de la santé publique. Représentation graphique des données: répartition géographique par canton, âge et sexe. 2020. https://www.covid19.admin.ch/fr/epidemiologic/case?detTime=total
26 Tilman S. Rollenverteilung in Coronavirus-Zeiten: Mehr Hausarbeit und Kinderbetreuung – Frauen tragen die Last - Politik – Tagesspiegel. Der Tagesspiegel. 2020.
https://www.tagesspiegel.de/politik/rollenverteilung-in-coronavirus-zeiten-mehr-hausarbeit-und-kinderbetreuung-frauen-tragen-die-last/25810728.html (accessed 7 Sep 2020).
27 Pinho-Gomes AC, Peters S, Thompson K, et al. Where are the women? Gender inequalities in COVID-19 research authorship. BMJ Glob Health. 2020;5:2922.
doi:10.1136/bmjgh-2020-002922
28 Rajan D, Koch K, Rohrer K, et al. Governance of the Covid-19 response: a call for more inclusive and transparent decision-making. BMJ Glob Health. 2020;5:e002655.
doi:10.1136/bmjgh-2020-002655
29 World Health Organization. WHO | Nonclinical evaluation of vaccines. World Health Organization 2005.
30 Scott PE, Unger EF, Jenkins MR, et al. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. J Am Coll Cardiol. 2018;71:1960–9.
doi:10.1016/j.jacc.2018.02.070
31 Pilote L, Raparelli V. Participation of Women in Clinical Trials: Not Yet Time to Rest on Our Laurels. J. Am. Coll. Cardiol. 2018;71:1970–2.
doi:10.1016/j.jacc.2018.02.069
32 Abi-Gerges N, Philp K, Pollard C, et al. Sex differences in ventricular repolarization: From cardiac electrophysiology to Torsades de Pointes. Fundam Clin Pharmacol. 2004;18:139–51.
doi:10.1111/j.1472-8206.2004.00230.x
33 Shiau S, Kuhn L, Strehlau R, et al. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr. 2014;14:39.
doi:10.1186/1471-2431-14-39
34 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) - Full Text View - ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04322682 (accessed 7 Sep 2020).
35 Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.
doi:10.1056/NEJMoa1912388
36 UN WOMEN. The COVID-19 shadow pandemic: Domestic violence in the world of work: A call to action for the private sector. Digital library: Publications. UN Women – Headquarters. 2020.
https://www.unwomen.org/en/digital-library/publications/2020/06/brief-domestic-violence-in-the-world-of-work#view (accessed 9 Sep 2020).
38 Bureau fédéral de l’égalité entre femmes et hommes. Violence domestique durant le coronavirus : situation stable dans la plupart des cantons. 2020.
https://www.ebg.admin.ch/ebg/fr/home/le-bfeg/nsb-news_list.msg-id-79335.html (accessed 9 Sep 2020).
39 Swiss National COVID-19 Science Task Force. Policy brief: Gender aspects of COVID19 and pandemic response. 2020. https://sciencetaskforce.ch/fr/policy-brief/inegalite-des-genres-dans-la-crise-du-covid-19/
40 Vindegaard N, Eriksen Benros M. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020;89:531–42.
doi:10.1016/j.bbi.2020.05.048